Synthekine Inc., an engineered cytokine therapeutics company, today announced that the company has dosed the first patient in the SYNERGY-101 study. SYNERGY-101 is a global, randomized Phase 2 ...
Cell division is a process of remarkable precision: during each cycle, the genetic material must be evenly distributed between the two daughter cells. To achieve this, duplicated chromosomes, known as ...
Completed the sale of FibroGen China to AstraZeneca for approximately $220 millionInitiated the Phase 2 monotherapy trial of FG-3246, a potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback